# EDGAR Filing Document

**Accession Number:** 0001640455
**File Stem:** 0001640455-23-000028
**Filing Date:** 2023-3
**Character Count:** 17906
**Document Hash:** 1f873fa64fd9b3958ba2007d7b881fa5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001640455-23-000028.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001640455-23-000028

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230310

**EFFECTIVENESS DATE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Jounce Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001640455
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **IRS NUMBER:** 454870634
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270481
- **FILM NUMBER:** 23725421

**BUSINESS ADDRESS:**
- **STREET 1:** 780 MEMORIAL DRIVE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 857-259-3840

**MAIL ADDRESS:**
- **STREET 1:** 780 MEMORIAL DRIVE
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

**As filed with the Securities and Exchange Commission on March 14, 2023**

**Registration No. 333**-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM S-8**

**Registration Statement**

**Under The Securities Act of 1933**

**JOUNCE THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

&nbsp;&nbsp;&nbsp;&nbsp;

---

| | |
|:---|:---|
| **Delaware**<br>(State or other jurisdiction of<br>incorporation or organization) | **45-4870634**<br>(I.R.S. Employer<br>Identification No.) |
| **780 Memorial Drive**<br>**Cambridge, Massachusetts**<br>(Address of principal executive offices) | **02139**<br>(Zip Code) |
| **Jounce Therapeutics, Inc. 2017 Stock Option and Incentive Plan**<br>**Jounce Therapeutics, Inc. 2017 Employee Stock Purchase Plan**<br>(Full title of the plan) | **Jounce Therapeutics, Inc. 2017 Stock Option and Incentive Plan**<br>**Jounce Therapeutics, Inc. 2017 Employee Stock Purchase Plan**<br>(Full title of the plan) |

---

**______________________________________________________________________________________________________**

---

| |
|:---|
| **Richard Murray, Ph.D.**<br>**Chief Executive Officer and President**<br>**Jounce Therapeutics, Inc.**<br>**780 Memorial Drive**<br>**Cambridge, Massachusetts 02139**<br>(Name and address of agent for service) |
| **(857) 259-3840**<br>(Telephone number, including area code, for agent for service) |

---

**________________________________________________________________________________________________________**

&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ◻ | Accelerated filer | ◻ |
| Non-accelerated filer | ⌧ | Smaller reporting company | ⌧  |
| | | Emerging growth company | ◻ |

---

&nbsp;&nbsp;&nbsp;&nbsp;If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ◻

------

**STATEMENT OF INCORPORATION BY REFERENCE**

This Registration Statement on Form S-8 is being filed to register an additional 2,067,769 shares of Common Stock, par value $0.001 per share (the "Common Stock"), of Jounce Therapeutics, Inc. (the "Registrant") issuable under the Registrant's 2017 Stock Option and Incentive Plan (the "2017 Option Plan") and an additional 516,942 shares of Common Stock issuable under the Registrant's 2017 Employee Stock Purchase Plan (the "2017 ESPP"). Pursuant to General Instruction E to Form S-8, except as otherwise set forth below, this Registration Statement on Form S-8 incorporates by reference the contents of:

• the Registration Statement on Form S-8, File No. 333-215794, filed by the Registrant with the Securities and Exchange Commission on January 27, 2017 relating to the 2017 Option Plan and 2017 ESPP, except for Item 8, Exhibits;

• the Registration Statement on Form S-8, File No. 333-223519, filed by the Registrant with the Securities and Exchange Commission on March 8, 2018 relating to the 2017 Option Plan and 2017 ESPP, except for Item 8, Exhibits;

• the Registration Statement on Form S-8, File No. 333-230088, filed by the Registrant with the Securities and Exchange Commission on March 6, 2019 relating to the 2017 Option Plan and 2017 ESPP, except for Item 8, Exhibits;

• the Registration Statement on Form S-8, File No. 333-236687, filed by the Registrant with the Securities and Exchange Commission on February 27, 2020 relating to the 2017 Option Plan and 2017 ESPP, except for Item 8, Exhibits;

• the Registration Statement on Form S-8, File No. 333-253496, filed by the Registrant with the Securities and Exchange Commission on February 25, 2021 related to the 2017 Option Plan and 2017 ESPP, except for Item 8, Exhibits; and

• the Registration Statement on Form S-8, File No. 333-263215, filed by the Registrant with the Securities and Exchange Commission on March 2, 2022 related to the 2017 Option Plan, 2017 ESPP and Stock Option Inducement Award, except for Item 8, Exhibits.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 8. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description of Exhibit** |
| <u>[4.1](http://www.sec.gov/Archives/edgar/data/1640455/000164045518000030/jnce12312017exhibit31.htm)</u> | <u>[Fourth Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 of the Registrant's Annual Report on Form 10-K (File No. 001-37998) filed March 8, 2018)](http://www.sec.gov/Archives/edgar/data/1640455/000164045518000030/jnce12312017exhibit31.htm)</u> |
| <u>[4.2](http://www.sec.gov/Archives/edgar/data/1640455/000164045518000030/jnce12312017exhibit32.htm)</u> | <u>[Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 of the Registrant's Annual Report on Form 10-K (File No. 001-37998) filed March 8, 2018)](http://www.sec.gov/Archives/edgar/data/1640455/000164045518000030/jnce12312017exhibit32.htm)</u> |
| <u>[4.3](http://www.sec.gov/Archives/edgar/data/1640455/000104746916017325/a2230513zex-4_1.htm)</u> | <u>[Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 of the Registrant's Registration Statement on Form S-1 (File No. 333-215372) filed December 30, 2016)](http://www.sec.gov/Archives/edgar/data/1640455/000104746916017325/a2230513zex-4_1.htm)</u> |
| <u>[5.1](jnce03102023exhibit51.htm)</u> | <u>[Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant](jnce03102023exhibit51.htm)</u> |
| <u>[23.1](jnce03102023exhibit51.htm)</u> | <u>[Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)](jnce03102023exhibit51.htm)</u> |
| <u>[23.2](jnce03102023s-8exhibit232.htm)</u> | <u>[Consent of Ernst & Young LLP, independent registered public accounting firm](jnce03102023s-8exhibit232.htm)</u> |
| <u>[24.1](#ida67d4a78ba345cba3d3de109b668e3d_7)</u> | <u>[Power of Attorney (included on the signature page of this registration statement)](#ida67d4a78ba345cba3d3de109b668e3d_7)</u> |
| <u>[99.1](http://www.sec.gov/Archives/edgar/data/1640455/000104746917000189/a2230618zex-10_1.htm)</u> | <u>[Jounce Therapeutics, Inc. 2017 Stock Option and Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant's Registration Statement on Form S-1/A (File No. 333-215372) filed January 17, 2017)](http://www.sec.gov/Archives/edgar/data/1640455/000104746917000189/a2230618zex-10_1.htm)</u> |
| <u>[99.2](http://www.sec.gov/Archives/edgar/data/1640455/000164045517000052/jnce09302017exhibit101.htm)</u> | <u>[Jounce Therapeutics, Inc. 2017 Employee Stock Purchase Plan, as amended (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-37998) filed November 13, 2017)](http://www.sec.gov/Archives/edgar/data/1640455/000164045517000052/jnce09302017exhibit101.htm)</u> |
| <u>[107\*](exhibit1071.htm)</u> | <u>[Filing Fee Table](exhibit1071.htm)</u> |
| \* | Filed herewith |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts on this 10<sup>th</sup> day of March, 2023.

---

| | |
|:---|:---|
| | **JOUNCE THERAPEUTICS, INC.** |
| By: | /s/ Richard Murray |
|  | Richard Murray, Ph.D. |
|  | President and Chief Executive Officer |

---

**POWER OF ATTORNEY AND SIGNATURES**

We, the undersigned officers and directors of Jounce Therapeutics, Inc., hereby severally constitute and appoint Richard Murray and Kim C. Drapkin and each of them singly, our true and lawful attorneys with full power to them, and each of them singly, to sign for us and in our names in the capacities indicated below, the registration statement on Form S-8 filed herewith and any and all subsequent amendments to said registration statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Jounce Therapeutics, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Richard Murray | President, Chief Executive Officer and Director (Principal Executive Officer) | March 10, 2023 |
| Richard Murray, Ph.D. |  |  |
| /s/ Kim C. Drapkin | Treasurer and Chief Financial Officer<br>(Principal Financial and Accounting Officer) | March 10, 2023 |
| Kim C. Drapkin |  |  |
| /s/ Jigar Raythatha | Chairman of the Board of Directors | March 10, 2023 |
| Jigar Raythatha |  |  |
| /s/ Luis A. Diaz, Jr. | Director | March 10, 2023 |
| Luis A. Diaz, Jr., M.D. |  |  |
| /s/ Barbara Duncan | Director | March 10, 2023 |
| Barbara Duncan |  |  |
| /s/ Robert Iannone | Director | March 10, 2023 |
| Robert Iannone, M.D., M.S.C.E. |  |  |
| /s/ Robert Kamen | Director | March 10, 2023 |
| Robert Kamen, Ph.D. |  |  |
| /s/ Perry Karsen | Director | March 10, 2023 |
| Perry Karsen |  |  |
| /s/ Luisa Salter-Cid | Director | March 10, 2023 |
| Luisa Salter-Cid, Ph.D. |  |  |

---

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Table**

**Form S-8**

(Form Type)

**Jounce Therapeutics, Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Newly Registered Securities**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered**<sup>(1)</sup> | **Proposed Maximum Offering Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common Stock, par value $0.001 per share | Other | 2584711<sup>(2)</sup> | $1.016<sup>(3)</sup> | $2626066.38 | $110.20 per $1,000,000 | $289.39 |
| **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $2626066.38 |  | $289.39 |
| **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  | $0.00 |
| **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $289.39 |

---

(1)In accordance with Rule 416(c) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions.

(2)Consists of 2,067,769 shares of Common Stock authorized for issuance under the Jounce Therapeutics, Inc. 2017 Stock Option and Incentive Plan and 516,942 shares of Common Stock authorized for issuance under the Jounce Therapeutics, Inc. 2017 Employee Stock Purchase Plan, as amended.

(3)Estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and 457(h) of the Securities Act and based upon the average of the high and low prices of the Registrant's Common Stock as reported on the Nasdaq Global Select Market on March 8, 2023.

## Exhibit 5.1

**Exhibit 5.1**

![image_1.jpg](image_1.jpg)

March 10, 2023

Jounce Therapeutics, Inc.

780 Memorial Drive

Cambridge, MA 02139

Re: Registration Statement on Form S-8; 2017 Stock Option and Incentive Plan; 2017 Employee Stock Purchase Plan

Ladies and Gentlemen:

We have assisted in the preparation of a Registration Statement on Form S-8 (the "<u>Registration Statement</u>") to be filed with the Securities and Exchange Commission (the "<u>Commission</u>") under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), relating to (i) an aggregate of 2,067,769 shares (the "<u>Plan Shares</u>") of common stock, $0.001 par value per share (the "<u>Common Stock</u>"), of Jounce Therapeutics, Inc., a Delaware corporation (the "<u>Company</u>"), issuable under the Company's 2017 Stock Option and Incentive Plan (the "<u>2017 Plan</u>") and (ii) an aggregate of 516,942 shares (the "<u>ESPP Shares</u>," and together with the Plan Shares, the "<u>Shares</u>") of Common Stock of the Company pursuant to the Company's 2017 Employee Stock Purchase Plan (together with the 2017 Plan, the "<u>Plans</u>").

We have examined the Certificate of Incorporation and By-Laws of the Company, each as amended and restated to date, and originals, or copies certified to our satisfaction, of all pertinent records of the meetings of the directors and stockholders of the Company, the Registration Statement and such other documents relating to the Company as we have deemed material for the purposes of this opinion.

In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified, photostatic or other copies, the authenticity of the originals of any such documents and the legal competence of all signatories to such documents.

We assume that the appropriate action will be taken, prior to the offer and sale of the Shares in accordance with the Plans, to register and qualify the Shares for sale under all applicable state securities or "blue sky" laws.

We express no opinion herein as to the laws of any state or jurisdiction other than the state laws of the Commonwealth of Massachusetts, the General Corporation Law of the State of Delaware and the federal laws of the United States of America.

It is understood that this opinion is to be used only in connection with the offer and sale of the Shares while the Registration Statement is in effect.

------

![image_1.jpg](image_1.jpg)

Jounce Therapeutics, Inc.

March 10, 2023

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized for issuance and, when the Shares are issued and paid for in accordance with the terms and conditions of the Plans, the Shares will be validly issued, fully paid and nonassessable.

We hereby consent to the filing of this opinion with the Commission in connection with the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K under the Securities Act. In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission.

Very truly yours,

&nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;

<u>/s/ WILMER CUTLER PICKERING HALE AND DORR LLP&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> 

WILMER CUTLER PICKERING HALE AND DORR LLP&nbsp;&nbsp;&nbsp;&nbsp;

## Exhibit 23.2

**Exhibit 23.2**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Jounce Therapeutics, Inc. 2017 Stock Option and Incentive Plan and the Jounce Therapeutics, Inc. 2017 Employee Stock Purchase Plan of our report dated March 10, 2023, with respect to the consolidated financial statements of Jounce Therapeutics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Boston, Massachusetts

March 10, 2023

<br>